Table 2.
Logistic regression analysis of factors associated with SARS-CoV-2 seroprevalence within the pandemic cancer populations.
| Cancer Population | Unadjusted Analysis | p-Value | Adjusted Analysis | p-Value |
|---|---|---|---|---|
| Cancer type | ||||
| Breast cancer | 2.379 (1.012–5.592) | 0.047 | 2.023 (0.705–5.801) | 0.19 |
| Cervical cancer | 2.249 (1.105–4.580) | 0.026 | 1.984 (0.783–5.029) | 0.149 |
| Hematological malignancies | 1.133 (0.305–4.216) | 0.852 | 0.985 (0.255–3.805) | 0.982 |
| Other solid malignancies | 2.042 (0.989–4.216) | 0.054 | 1.885 (0.814–4.362) | 0.139 |
| Kaposi’s sarcoma | ref | ref | ||
| Age | 0.997 (0.983–1.011) | 0.653 | 0.992(0.977–1.007) | 0.29 |
| Sex | ||||
| Female | 1.257 (0.965–1.637) | 0.2346 | 1.121 (0.615–2.043) | 0.7089 |
| Male | ref | ref | ||
| HIV status | ||||
| Negative | 1.193 (0.783–1.818) | 0.4106 | 1.1 (0.672–1.801) | 0.705 |
| Positive | ref | ref | ||
| Received TB vaccination | ||||
| Yes | 1.358 (0.917–2.013) | 0.3074 | 1.401 (0.767–2.558) | 0.2731 |
| No | ref | ref | ||
| COVID-19-related symptoms | ||||
| Yes | 0.755 (0.488–1.166) | 0.2052 | 0.726 (0.465–1.135) | 0.1604 |
| No | ref | ref | ||
| Household size | 0.992 (0.924–1.064) | 0.8181 | 0.984 (0.915–1.059) | 0.6702 |
Note: TB denotes tuberculosis.